To design and direct at will the specificity of T cells in a non-major histocompatibility complex (MHC)-restricted manner, we have generated and expressed chimeric T-cell receptor (TcR) genes composed of the TcR constant (C) domains fused to the antibody's variable (V) domains. Genomic expression vectors have been constructed containing the rearranged gene segments coding for the V region domains of the heavy (VH) and light (VL) chains of an anti-2,4,6-trinitrophenyl (TNP) antibody (SP6) spliced to either one of the C-region gene segments of the a or (3 TcR chains. Following transfection into a cytotoxic T-cell hybridoma, expression of a functional TcR was detected. The chimeric TcR exhibited the idiotope of the Sp6 anti-TNP antibody and endowed the T cells with a non-MHC-restricted response to the hapten TNP. The transfectants specifically killed and produced interleukin 2 in response to TNP-bearing target cells across strain and species barriers. Moreover, such transfectants responded to immobilized TNPprotein conjugates, bypassing the need for cellular processing and presentation. In the particular system employed, both the TNP-binding site and the Sp6 idiotope reside almost exclusively in the VH chain region. Hence, introduction into T cells of TcR genes containing only the VHSp6 fused to either the Ca or C(3 was sufficient for the expression of a functional surface receptor. Apparently, the VHCa or VHCP chimeric chains can pair with the endogenous ( or a chains ofthe recipient T cell to form a functional a(3 heterodimeric receptor. Thus, this chimeric receptor provides the T cell with an antibody-like specificity and is able to effectively transmit the signal for T-cell activation and execution of its effector function.
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meric TcR" (cTcR) would contain the extracellular C region, the transmembrane segment, and the cytoplasmic domains of normal TcRs and should therefore be able to function normally to induce T-cell proliferation, interleukin production, and target cell lysis.
Spontaneous transcription of an aberrantly joined IgVH gene and a TcR JaCa gene resulting from site-specific chromosome 14 inversion in human T-cell tumors was reported (4-6); however, no protein product was detected. Chimeric fusion proteins have also been produced in myelomas by the introduction of the TcR C exons between the VK and CK exons (7) . More recent reports have shown that a chimeric protein containing the TcR V,, domain and the immunoglobulin C domain can be synthesized in myeloma cells. This protein associates with normal L chains to form a secreted tetramer (8) . Attempts to assemble and secrete similar chimeric protein containing the VtC,-, and VC3CK have not been successful (9) .
The studies described above all reported the construction of nonfunctional chimeric Ig-TcR proteins. In this paper we describe the construction and functional expression in T cells of chimeric TcR genes made by recombining the immunoglobulin VH and VL rearranged gene segments to the C-region exons of the TcR a and 13 chains. The resulting cTcR is expressed on the surface of cytotoxic T lymphocytes, recognizes antigen in a non-MHC-restricted manner, and effectively transmits the transmembrane signal for T-cell activation.
Antigen recognition by T-cell receptors (TcRs) differs from that of antibodies in that antibodies interact with antigens in their native state with relatively high affinity, whereas TcRs recognize fragmented antigens bound to cell surface class I and class II major histocompatibility complex (MHC) molecules (1). The differences in specificity of TcRs versus antibodies are not, however, evident from differences in their molecular structure. In fact, both molecules consist of two disulfide-linked polypeptide chains referred to as a and ,3 for the TcR and heavy (H) and light (L) for antibodies, each containing constant (C) and variable (V) domains. The antigen-binding site of both antibodies and TcR is encoded by a V-region exon, formed by rearrangment of V, diversity and joining gene segments (reviewed in ref.
2). In the case of immunoglobulins, x-ray data have shown that the V regions are loosely connected to the C regions (3), and, because of their high degree of homology with immunoglobulin, it is highly likely that TcRs are constructed similarly. Therefore, from a structural standpoint, it should be possible to confer antibody specificity on T cells by removing TcR produce pRSV2VHCa and pRSV2VHC/3 ( Fig. 1) Cytotoxicity Assay. The 51Cr-release assay (15) was used to evaluate the ability of the transfectants to lyse specific target cells. Target cells were modified by TNP using 10 mM 2,4,6-trinitrobenzenesulfonic acid as described (22 ated with a different selectable marker (gpt or neor genes) than was its complementary chain, to allow selection of transfectants coexpressing both chimeric genes. To express these chimeric genes in T cells, we transfected them into the MD.45 murine hybridoma. The MD.45 hybridoma specifically lyses H-2Db target cells (15) and, upon stimulation with either T-cell mitogens or appropriate target cells, produces IL-2, interleukin 3, and granulocyte/macrophage colonystimulating factor. The hybridoma subclone used in this study expresses both of the a and ,B TcR chains of its CTL parent and only the 13 chain of BW5147 (23) . We first transfected into MD.45 each of the four chimeric constructs independently and analyzed the resulting transfectants for expression of chimeric transcripts. We then retransfected the positive clones with the complementary constructs.
In the first round of transfections with single chimeric genes, out of 48 wells seeded for each transfection, growth was seen in 21 of those that received VLCa (termed GTA.a), 15 that received VLCB (termed GTA.b), 9 that received VHCa (termed GTA.c), and 13 that received VHCP (termed GTA.d). Clones expressing high RNA levels of each series were then transfected with the complementary construct. In all, out of 3 x 107 cells transfected, 54 independent transfectants were obtained from GTA.a that received the VHCB construct (termed GTA.e), 13 from GTA.b that received VHCa (termed GTA.f), 10 from GTA.c that received VLCi3
(termed GTA.g), and 18 from GTA.d that received VLCa (termed GTA.h).
To determine which of the transfectants expressed VH and/or VL chimeric gene segments, we analyzed their RNA transcripts by Northern blot hybridization analysis using probes specific for the Sp6 VH ( Fig. 2A, upper panel) and VL ( Fig. 2A, lower Expression of the chimeric polypeptide chains was analyzed in cell lysates by immunoblotting using the anti-Sp6 idiotypic mAb 20.5 (Fig. 2B) . The idiotope recognized by this antibody is sensitive to reduction (G.G. and Z.E., unpublished data) and is expressed exclusively by the VH of the Sp6 ,u chain: the antiidiotypic mAb reacted only with transfectants that received chimeric genes containing VH either alone (such as c.2 and d.9, shown after longer exposure of the blot, right panel of Fig. 2B ) or together with VL chimeric genes (e-h, Fig. 2B ). The doubly transfected cells expressed a major broad band (apparently composed of two major bands of 85 and 90 kDa) that corresponds to heterodimeric proteins, bands of higher molecular mass of about 160 kDa, and higher molecular mass bands that most likely correspond to heterotetrameric and higher complexes of the chimeric receptor. Bands of about 38 kDa (in recipients of the VHCa chimeric genes) and 42 kDa (in VHCI3 recipients) are also apparent, representing the non-S-S linked, monomer chimeric chains present in the cell lysates. Similar blots of gels electrophoresed under reducing conditions or developed with a radioiodinated anti-mouse Fab' antibody failed to give any signal. hybridoma. The intensity of the different bands reflects the amount of the chimeric receptor in the cell lysates and the degree of reactivity with the antiidiotypic antibody.
Functional Expression of the Chimeric TcR Genes. To examine whether the chimeric TcR genes code for a functional receptor, we tested the ability of the various transfectants to produce lymphokines in response to TNP-modified cells and to kill target cells bearing TNP groups on their surface. When TNP-A.20, (a TNP-modified B-cell lymphoma from BALB/c mice), was used to stimulate the various transfectomas, almost all of the double transfectants produced IL-2 (Fig. 3) . No production of IL-2 was evident when unmodified A.20 cells were used as stimulators (data not shown) or when MD.45 hybridoma cells or transfectants that expressed only the chimeric VLCa (or CB) constructs were used as responders (GTA.a and GTA.b, Fig. 3 ). These cells were able to produce IL-2, as was evident by their ability to respond to EL-4 (the H-2b target cell of the MD.45 hybridoma). Interestingly, transfectants that received and expressed the VHCa (GTA.c) or VHCB (GTA.d) chimeric genes could be stimulated by TNP-A.20 cells, suggesting that the TNP-binding capacity, like the Sp6 idiotype, resides primarily within the Sp6 VH domain.
The cTcR recognized TNP in a non-MHC-restricted manner, as evident by the ability of the transfectants to respond to TNP-modified allogeneic and xenogeneic cells (Table 1) . Transfectants bearing the chimeric TcR could be activated by TNP groups bound directly to stimulator cells (Fig. 3, Table  1 ) or coupled to a protein carrier (such as TNP-bovine serum albumin) and presented either by antigen-presenting cells (APCs) such as A.20 and spleen cells (not shown) or adsorbed onto plastic substrate (Table 1) . TNP-modified proteins in solution inhibited specifically and in a dose-dependent manner the activation of the various transfectants by immobilized antigen (Fig. 4A) , indicating that, like antibodies, the cTcR was able to bind soluble antigen. Anti-SP6-idiotype as well as anti-TNP mAbs also inhibited completely the IL-2 production by the cells (Fig. 4 B and C) .
Another manifestation of the functional expression of the chimeric receptor, in the effector phase of T-cell response, is demonstrated by the ability ofthe transfectants to specifically kill haptenated target cells as measured by the 5"Cr-release 
DISCUSSION
In this article we have shown that chimeric TcR chains, composed of immunoglobulin V regions and the TcR C regions, can be functionally expressed in T cells. Expression of this cTcR endowed the recipient T cell with antibody-type specificity: it could recognize and respond to stimulator and target cells that bear the TNP haptenic group on their surfaces, as evident by either IL-2 production (Table 1 , Fig. 3 ) or cytolytic activity (Fig. 5) . The recognition ofTNP is non-MHC restricted, as manifested by the ability of recipients of the chimeric genes to respond to TNP-modified cells of different strains and species and to TNP adsorbed onto plastic, and is independent of the endogenous TcR of the recipient hybridoma. -The antibody-derived origin of the cTcR is further supported by the observation that the anti-Sp6 mAb 20.5 reacted with the chimeric receptor in immunoblotting (Fig. 2B ) and immunoprecipitation (24) and completely inhibited the activity of most of the transfectants toward TNP (Fig. 4) . Finally, like their parental antibody, Sp6, the cTcRs also bind TNP-modified antigens in solution (Fig. 4A) . The ability of soluble antigens to inhibit the stimulation of the transfectants provides us with direct methods to study the effect of physicochemical parameters, such as receptor affinity, and antigenic valency, density, and rigidity on T-cell activation. The Sp6 antibody-binding site is expressed on the transfectants regardless of which immunoglobulin V region was combined with which TcR C region domains. Both VHCa and VLC/8 or VHCP and VLCa chain combinations could pair, form sulfhydryl bonds, assemble with T3 molecules (ref. 25 and data not shown), and be expressed in the membrane of T cells as functional dimers that bind the hapten, display the Sp6 idiotope, and transmit a signal for T-cell activation. In most of the transfectants that received both chimeric genes, a tetrameric complex of about 160 kDa was also observed (Fig. 2B) ; however, its functional significance has yet to be established. Interestingly, in the experimental system we employed, using the Sp6 V domains, it appears that the VH by itself can account for most of the antibody-binding capacity and expression of the idiotypic determinant. Hence, transfectants receiving either VHCa or VHCP chimeric genes alone expressed functional receptors that bind TNP (GTA.c, GTA.d, Fig. 3 (24) . The fact that the H-chain V region contributes most of the contact residues in the binding site of several antibodies was established by studies that assigned antibody activity to isolated chains (26) . The structural similarity between the TcR Va and VB to the immunoglobulin VL, as manifested by the strong resemblance in their invariant amino acids (2) and distance between the cysteines that form the intrachain disulfide bond (23) , may explain the efficiency by which the VH chimeric chain pairs with either one of the endogenous TcRa or chains to yield an active binding site.
It is noteworthy that both quantitative and qualitative differences have been observed in the degree of reactivity and the ability of the different transfectants that received various combinations of chimeric genes to respond to different forms of antigen and stimulator cells. For example, the GTA.g series that was first transfected with VHCa and then with VLCB responded better to TNP-bovine serum albumin than did the GTA.f series that received the same chimeric gene combination in reverse order. The GTA.d series that was transfected only with VHCB could be better inhibited by the 20.5 mAb than the GTA.c series that received the VHCa gene. We believe that these differences are due to the level of expression of the chimeric TcR and the degree of pairing with the endogenous TcR chains. It is likely that pairing of the original VH and VL will result in the binding site with the highest affinity and specificity toward the hapten.
Our successful attempts to express functional chimeric TcRs that recognize antigen in a non-MHC-restricted manner pave the way for an approach for the design at will of TcRs of any desired specificity, provided that such specificity can be predefined by a mAb. Our ability to combine antibody specificity with T-cell-mediated target cell lysis may have clinical potential: it enables the construction of chimeric TcR genes using the V regions of antibodies directed at desired antigens on a given target cell. These chimeric genes, once produced, are non-MHC-restricted and universal in the sense that a given set of chimeric genes could then be transfected into T cells from any individual. Upon returning the cells to their donors, they should manifest the specificity of the cTcR by proliferating and mediating specific effector function (cytolysis, production of lymphokines, help, or suppression) when encountering their target cells. This approach can be exploited, for example, to direct cytotoxic T lymphocytes to kill tumor or virally infected cells. Construction of cTcRs with anti-tumor specificity will enable testing ofthe feasibility of this approach in combating human tumors.
We 
